Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 4/20 | 0.62 |
| ▸ | KMO | O15229 | 1/20 | 0.55 |
| ▸ | AXL | P30530 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.53 |
| ▸ | BAD | Q92934 | 1/20 | 0.53 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.52 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | CTRC | Q99895 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL122522 | 0.98 | DHODH (0.59) | DHODHKMOAXLEGFRBCL2L1 | |
| SCHEMBL30189265 | 0.87 | KMO (0.53) | DHODHKMOAXLHCAR1 | |
| SCHEMBL29772042 | 0.87 | HCAR1 (0.60) | DHODHEGFRBCL2L1BADHCAR1 | |
| SCHEMBL2160048 | 0.87 | KMO (0.53) | DHODHKMOAXLHCAR1 | |
| SCHEMBL18235913 | 0.87 | DHODH (0.49) | DHODHKMOAXLEGFRBCL2L1 | |
| SCHEMBL23671728 | 0.86 | DHODH (0.81) | DHODHKMOEGFRCTRC | |
| SCHEMBL2559182 | 0.84 | BCL2L1 (0.53) | DHODHBCL2L1BADHCAR1PPARA | |
| SCHEMBL4266117 | 0.83 | KMO (0.75) | DHODHKMOEGFRCTRC | |
| SCHEMBL1768904 | 0.83 | DHODH (0.77) | DHODHKMOEGFRCTRC | |
| SCHEMBL27736451 | 0.83 | DHODH (0.77) | DHODHKMOEGFRCTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | claimed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004701-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | DHODH 534/4885KMO 3110/4885AXL 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.